[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604429":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":18,"collaborators":10,"id":22,"slug":23,"hasResults":24,"nctId":25,"briefTitle":26,"officialTitle":27,"acronym":10,"eligibilityCriteria":28,"healthyVolunteers":24,"sex":29,"minAge":30,"maxAge":10,"enrollmentInfo":31,"targetDuration":10,"studyType":34,"phases":10,"briefSummary":35,"conditions":36,"keywords":38,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"SLE without Nephritis",null,"Patients diagnosed with systemic lupus erythematosus but without evidence of renal involvement. Clinical and laboratory data are collected to correlate IL-33 levels with disease activity excluding renal manifestations.",{"label":13,"type":10,"description":14,"interventionNames":10},"SLE with Lupus Nephritis","Patients with systemic lupus erythematosus and confirmed lupus nephritis via biopsy and clinical parameters. This group undergoes detailed renal Doppler imaging and biopsy assessment to evaluate the relationship of IL-33 with renal involvement.",{"label":16,"type":10,"description":17,"interventionNames":10},"Healthy Controls","Age- and sex-matched healthy individuals without autoimmune or renal disease, serving as baseline comparators for IL-33 serum levels and immune profiles.",{"type":19,"investigatorFullName":20,"investigatorTitle":21,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Marly Mamdouh","resident at the Rheumatology Department","100604429","association-of-serum-interleukin-33-levels-with-clinical-manifestations-in-systemic-lupus-erythematosus-100604429",false,"NCT07149402","Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus","Serum Interleukin-33 (IL-33) Levels and Their Association With Clinical Manifestations in Patients With Systemic Lupus Erythematosus and Lupus Nephritis at Assiut University Hospital","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* Diagnosed with systemic lupus erythematosus according to the American College of Rheumatology (ACR) criteria.\n* For the lupus nephritis group: confirmed diagnosis of lupus nephritis based on clinical, laboratory, and renal biopsy findings.\n* For the control group: healthy individuals matched for age and sex, with no history of autoimmune or renal diseases.\n\nExclusion Criteria:\n\n* Patients with other autoimmune diseases. Patients with chronic infections or malignancies. Pregnant or lactating women. Patients with end-stage renal disease (ESRD) or on dialysis. Individuals who refuse to provide informed consent.","ALL","18 Years",{"count":32,"type":33},150,"ESTIMATED","OBSERVATIONAL","This is a case-control study investigating serum IL-33 levels and their association with clinical manifestations in systemic lupus erythematosus (SLE). The study compares IL-33 levels in three groups: SLE patients with lupus nephritis, SLE patients without nephritis, and healthy controls. The goal is to clarify IL-33's role as a biomarker reflecting disease activity and organ involvement, especially renal pathology.",[37],"SLE",[37,39],"IL-33","NOT_YET_RECRUITING","2025-08-28",{"date":43,"type":44},"2025-09-02","ACTUAL",{"date":46,"type":33},"2026-08-30",{"date":48,"type":33},"2027-12-30",{"name":5,"class":6}]